Anthem Biosciences share price today

Anthem Biosciences Ltd's share price was ₹888.30 at the close on 4 November 2026. It has been rising for 25 weeks. That is 11.2% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹588 and ₹958, and at that close it sat 81% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Anthem Biosciences Ltd is in stage 2. The phase helps read everything below.

Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 17 weeks in a row.

Over the last 1 year the share price moved +17% while the NIFTY 500 moved −5%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

One change stood out: promoters cut their stake for 3 quarters in a row.

1. Promoters cut their stake for 3 quarters in a row

   From 74.7% to 71.4% of the company by the September 2026 quarter.

For April to June 2026 (the quarter ended 30 June 2026), Anthem Biosciences reported revenue of ₹418 crore, down 22.6% from ₹540 crore a year earlier, and a profit of ₹120 crore, down 11.8% from ₹136 crore.

Anthem Biosciences results: April to June 2026 against a year earlier

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

Anthem Biosciences' management discussed these results on a call held on 22 July 2026; what it said is further down this page.

From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.

Anthem Biosciences closed at ₹888.30 on 4 November 2026, up 27.5% from ₹696.55 a year earlier (7 November 2025). Its highest weekly close since July 2025 was ₹940.90 on 11 September 2026.

Anthem Biosciences share price: then and now

Weekly closing prices. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

75 weekly closes from 25 July 2025 to 4 November 2026.

4 Nov 2026: Anthem Biosciences closed at ₹888.30, up 7.2% on the week and up 3.8% on the month. 22 Jul 2026: Anthem Biosciences held its results call for April to June 2026. Management guided: FY27 revenue growth to remain aligned with long-term historical performance, described in Q&A as double-digit.

Earlier

• Results for April to June 2026: Revenue down 22.6% and profit down 11.8% on a year earlier.
• 25 Jun 2026: ex-date for a dividend of ₹2 a share, record date 26 Jun 2026.
• Our read, 31 May 2026: Vertically integrated CRDMO with backward integration driving margin step-up; Unit 4 doubles capacity by FY28 at inflection point where destocking ends and commercial-molecule mix accelerates.

Our read of the business

Anthem runs the most backward-integrated peptide/API manufacturing platform in India, fermentation through synthesis in one complex. FY26 operating margin hit 43.4% (vs 38% prior year) as outsourced intermediates were eliminated. With destocking now mostly behind, Unit 4 capital spending of ₹1,200 crore positions Anthem to double custom synthesis capacity by March 2028, entering FY29 with double the asset base at operating leverage that has already been proven.

Latest quarter: Highest-ever quarterly revenue and margins; Unit 4 capital spending finalised.

Our read after the latest results, written 31 May 2026.

Anthem Biosciences paid ₹2 a share in regular dividends in the 12 months to 5 November 2026 (1 payment), a yield of 0.23% at the ₹888.30 close on 4 November 2026. The last was a dividend of ₹2 a share, ex-date 25 June 2026.

Anthem Biosciences dividends since 1 April 2021

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date.

Yes. Anthem Biosciences Ltd paid out 19% of its profit as dividends in FY26, and it paid a dividend in 1 of its last 7 reported years.

From the NSE corporate-actions record, read 5 November 2026.

On the call for April to June 2026, held on 22 July 2026, Anthem Biosciences' management guided: FY27 revenue growth to remain aligned with long-term historical performance, described in Q&A as double-digit.

“We have a very high degree of visibility because we already have an order book for 60% of what we need to do.”Ajay Bharadwaj, CEO, on the call for April to June 2026

What management guided

• Q2-Q4 delivery volumes and capacity utilization to improve after Q1, with Q1 viewed as the softest quarter.
• FY27 operating profit and profit margins to remain broadly intact, with management confident of defending the current margin profile.
• Full-year employee cost expected at 12.0%-13.0% of sales and other expenses at 9.0%-10.0%.
• Unit 4 Phase 1: ₹1,200 crore capital spending, 365 kiloliters of custom synthesis and 100 kiloliters of fermentation capacity, planned readiness by end FY28.

Management’s own plans and goals, from our notes of the call. A plan is not a result.

Source: the call transcript.

From the call for April to June 2026, 22 July 2026.

What is changing at Anthem Biosciences, from the latest results and calls: backward integration margin expansion, commercial molecule mix shift and unit 4 capacity expansion.

• Backward Integration Margin Expansion. Eliminating outsourced intermediates drove operating profit from 38% to 43.4%. The gain is now baked into the cost structure, not a temporary benefit. ⚠ estimate
• Commercial Molecule Mix Shift. Commercial molecules at 60% of revenues, with 4 newly commercialised in FY26 contributing 8-9% and a 2-3 year ramp trajectory ahead. ⚠ estimate
• Unit 4 Capacity Expansion. ₹1,200 crore capital spending adds 365 kL custom synthesis and 100 kL fermentation by March 2028, more than doubling the synthesis base. ⚠ estimate
• GLP-1 API Import Replacement. Indian regulatory approvals for GLP-1 formulations are proliferating; Anthem is in advanced discussions with all major pharma players for GLP-1 API supply to replace current Chinese imports. ⚠ estimate

We check 16 kinds of change in every company, such as costs spread over more sales, higher-value products, new orders, new regions or falling debt, against its reported numbers and what management said on its calls. Only changes the numbers back are shown.

Our read after the latest results, written 31 May 2026.

March 2028 goal for Unit 4 Phase 1 is a greenfield build. A 6-month slip pushes the capacity-driven revenue inflection to FY29.

The main risks

• Unit 4 Commissioning Slippage: March 2028 goal for Unit 4 Phase 1 is a greenfield build. A 6-month slip pushes the capacity-driven revenue inflection to FY29. ✓ fact
• GLP-1 Revenue Timeline Risk: 6-8 month commercialisation window depends on customer regulatory approvals outside Anthem's control. ✓ fact
• Capital spending Funding and Cash Burn: ₹700 crore FY27 capital spending against net cash of ₹785 crore as of June 2025, thin buffer if operating cash generation slows during the build. ✓ fact
• Management Guidance Consistency: Three documented guidance changes in 4 calls, revenue cut, capital spending increase, capacity spec reduction, create uncertainty about planning discipline. ✓ fact

Our read after the latest results, written 31 May 2026.

When Anthem Biosciences reports July to September 2026, these are the 4 checks that show whether the story is still on course. First: Q2 CRDMO revenue and Unit 2 utilization should show the expected rebound as deferred customer deliveries begin moving through the facilities.

Anthem Biosciences is on 3 of our India lists: Momentum stocks, Small & mid cap stocks and Pharma stocks.

Anthem Biosciences Ltd earned ₹120 Cr of net profit in the Jun 2026 quarter, −11.8% on the same quarter a year earlier. Full-year FY26 profit was ₹592 Cr. Over 6 years profit has grown 36.1% a year on average. That is 28.7% of the quarter's revenue. The same quarter a year earlier earned ₹136 Cr.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

For the full year, FY26 profit was ₹592 Cr (+31.3% on the year before).

Why profit moved: revenue changed −22.6% on a year earlier and the margin moved +1.0 percentage points. Sales did the work, and the margin was about flat.

On average over the last four quarters, profit changed +24.7% and revenue −1.6%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit.

Anthem Biosciences Ltd reported ₹418 Cr of revenue in the Jun 2026 quarter, −22.6% on the same quarter a year earlier. Over 6 years it has grown 22.4% a year on average. The last full year, FY26, came in at ₹2,124 Cr. The last four reported quarters add to ₹2,002 Cr.

Revenue is everything the company billed its customers in the period.

FY26 revenue was ₹2,124 Cr, +15.1% on the year before.

Recent pace: the last four quarters grew −1.6% on average, against 22.4% a year over the longer run, so this year is growing slower than its own long-run rate.

Anthem Biosciences Ltd's operating margin was 36.0% in the Jun 2026 quarter, 1.0 percentage points higher than the same quarter a year ago. Across 7 years it has been between 29.0% and 46.0%. The latest quarter is within that range.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed +0.5 percentage points on the year while gross margin changed +7.8 points. So the gain came mostly from the gross margin, which means input costs and prices charged.

Over the last 3 years, 89% of Anthem Biosciences Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹844 Cr of operating cash against ₹592 Cr of profit. After ₹179 Cr of spending on assets, ₹665 Cr was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 89% of profit came in as cash: the cash cycle got 61 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives.

What to look at next: the bigger use of cash is spending on new assets, at 2.4× depreciation over three years. The next section checks what that spending is building.

Anthem Biosciences Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 124 days in FY26, up from 63 days in FY21. It spent ₹739 Cr on assets over the last 3 years. Customers take 101 days to pay, and stock sits for 56 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹2,124 Cr, each day of that cycle ties up about ₹5.8 Cr, so roughly ₹722 Cr is tied up in the business at any time.

FY26: customers took 101 days to pay and stock sat for 56 days, about 1.8 months of sales sitting as stock, for a full cycle of 124 days, longer than FY21's 63.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 56 days. Customers pay about 101 days after that. Suppliers are paid at 34 days. Together that makes the 124-day cycle.

Spending on assets: ₹739 Cr over the last 3 years, against ₹305 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹264 Cr (FY26): assets paid for that are not earning yet.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

Anthem Biosciences Ltd's P/E is 84.3×, in the middle of its own history: higher than 62% of past readings. Its usual P/E (the middle reading) is 78.0×, over 1 year of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Jun 2026 add up to ₹10.25.

Why the multiple is where it is: over the past year earnings per share moved +30.6% while the price moved +27.5%. Earnings did better than the price, which pulled the multiple down within its own range.

In short: the multiple is about average against its own past, so the earnings trend underneath matters more than the multiple.

Anthem Biosciences Ltd's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 6 quarters of 1 measure, with some gaps.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Why it matters: with too little history, we say so rather than guess a direction.

One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result.

There are fewer than eight usable quarters, so this page does not guess a direction from so little history.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the share price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

FY26 revenue 18% on a year earlier to ₹2,124 crore, operating profit 43.4% margin; declined M&A, refused over-leverage.

Regulatory and governance record

SEBI Code-of-Conduct / PIT violation by a designated person trading during window closure; to Audit Committee. No promoter/SEBI action (RHP: no disciplinary action vs promoters in last 5 fiscals).

Checked 7 June 2026.

Anthem Biosciences Ltd earned a ROCE of 30% in FY26. That is up from a low of 24% in FY24. Its return on capital used (ROIC) is 10.2 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 27.9% net margin and 0.62× asset turnover (sales divided by assets).

Return on capital employed (ROCE) is the profit the whole business earns on all the money in it, from shareholders and lenders together. It is the best single test of whether growth adds value or just size.

Why the return is what it is (FY26): a 27.9% net margin × 0.62× asset turnover × 1.13× leverage (assets divided by equity) ≈ 19.5% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed.

The key test, return on capital used minus the cost of capital: 22.2% − 12.0% = +10.2 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. A gap this wide means each rupee put back into the business creates more than a rupee of value.

The 22.2% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 24.2%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method.

Anthem Biosciences Ltd has total debt of ₹54.0 Cr against shareholder equity of ₹3,043 Cr as of Jun 2026, so its debt is 0.02× its equity, which is very little. Year by year, that ratio went from 0.12 in FY24 to 0.02 in FY26. So the returns on this page come from the business, not from borrowed money.

Debt-to-equity shows how much of the business is paid for with borrowed money. Lower is safer, and the direction matters as much as the level.

Domestic institutions raised their stake in Anthem Biosciences Ltd by 4.9 percentage points over 4 quarters, the biggest change among its owners. Domestic institutions now own 12.1% of the company. Promoters moved −3.3 points over the same period, to 71.4%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings.

Who owns the company each quarter: promoters (the founders or controlling owners), foreign institutions, domestic institutions such as mutual funds, and the public. When people close to the business steadily raise their stake, that is worth noticing; a quiet list is also an answer.

Over the last two years: Domestic institutions: +4.9 points over 4 quarters, to 12.1%; Promoters: −3.3 points over 4 quarters, to 71.4%; Foreign institutions: +2.1 points over 4 quarters, to 3.8%.

Why the owners changed: domestic institutions drove it (+4.9 points), with the other side taken by promoters (−3.3 points). They raised their stake step by step.

For Anthem Biosciences Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date.

The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.

46.7 out of 100, rank 15 of 24 in Pharma - API & CRAMS, with 89% of the evidence available.

Anthem Biosciences Ltd scores 46.7 out of 100 against the 24 companies it is compared with in Pharma - API & CRAMS, ranking 15. A strong business with a high valuation: it would need rising earnings, or a lower multiple, to score better on value.

The four parts add up to the total exactly: 12.5 + 23.4 + 4.9 + 5.9 = 46.7. This is the same number shown on the industry page; it is worked out once for the whole group and read here.

What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector.

Anthem Biosciences ranks 15 of 24 Pharma - API & CRAMS companies on the 4-Factor Sector Score, with 46.7 out of 100.

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read.

The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section.

Related companies: Pharma - API & CRAMS, all 24 compared on one page.

Anthem Biosciences is the 4th largest of 24 Pharma - API & CRAMS companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Divis Laboratories, Laurus Labs and Gland Pharma. Just below it: Sai Life Sciences, Acutaas Chemicals and Piramal Pharma.

Pharma - API & CRAMS companies close in size

1. Divis Laboratories Ltd ₹2,59,628 crore
2. Laurus Labs Ltd ₹1,29,972 crore
3. Gland Pharma Ltd ₹51,086 crore
4. Anthem Biosciences Ltd ₹46,689 crore
5. Sai Life Sciences Ltd ₹33,093 crore
6. Acutaas Chemicals Ltd ₹32,778 crore
7. Piramal Pharma Ltd ₹31,807 crore

All 24 Pharma - API & CRAMS companies, largest first

Companies close in size in other industries

203. Godrej Properties Ltd ₹47,232 crore · Realty - National
204. Aditya Infotech Ltd ₹46,739 crore · CCTV Camera
205. Anthem Biosciences Ltd ₹46,689 crore
206. Gujarat Fluorochemicals Ltd ₹46,666 crore · Chemicals - Flourine
207. PB Fintech Ltd ₹46,280 crore · Insurance - Proxy

Sector Alpha, written by code from the published numbers. Data as of 4 November 2026.

Every chart on this page is drawn by code from the published figures, with no forecasts and no price opinions.

See the plain-text version of this page.